| Identification | Back Directory | [Name]
(2E)-3-(4'-Hydroxy-3'-tricyclo[3.3.1.13,7]dec-1-yl[1,1'-biphenyl]-4-yl)-2-propenoic acid | [CAS]
496868-77-0 | [Synonyms]
ST 1926
Adarotene
Adarotene (ST1926)
ST 1926;ST-1926;ST1926
ADAROTENE;ST 1926;ST-1926;ST1926
(E)-3-[4-[3-(1-adamantyl)-4-hydroxyphenyl]phenyl]prop-2-enoic acid
(2E)-3-(4'-Hydroxy-3'-tricyclo[3.3.1.13,7]dec-1-yl[1,1'-biphenyl]-4-yl)-2-propenoic acid
2-Propenoic acid, 3-(4'-hydroxy-3'-tricyclo[3.3.1.13,7]dec-1-yl[1,1'-biphenyl]-4-yl)-, (2E)- | [Molecular Formula]
C25H26O3 | [MOL File]
496868-77-0.mol | [Molecular Weight]
374.47 |
| Chemical Properties | Back Directory | [Melting point ]
>240 °C | [Boiling point ]
574.1±50.0 °C(Predicted) | [density ]
1.257 | [storage temp. ]
Store at -20°C | [solubility ]
≥37.4 mg/mL in DMSO; insoluble in H2O; ≥10.97 mg/mL in EtOH with gentle warming and ultrasonic | [form ]
solid | [pka]
-95.54±0.10(Predicted) | [color ]
White to green |
| Hazard Information | Back Directory | [Uses]
Adarotene has been found to have antitumor activity against different types of cancer, including acute myeloid leukemia, primary effusion lymphoma, prostate cancer and glioma. It may also be useful in treating acute lung injury through inflammation and ROS suppression via inactivating TLR4?/NF-?κB and p38?/ERK1?/2 signaling pathways. | [target]
RAR β |
|
|